Clinical Trial Update: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial of olaparib in germline BRCA1/2 mutated pancreatic cancer after non-progression on platinum therapy has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas | Phase 3 | Status: COMPLETED | Results posted: 2020-01-27